Clinical Trial Update: A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating subcutaneously administered rAvPAL-PEG in phenylketonuria has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• rAvPAL-PEG (recombinant phenylalanine ammonia-lyase enzyme PEGylated)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria | Phase 2 | Status: COMPLETED | Results posted: 2019-02-27